Fenoterol Delivery by Respimat® Soft Mist Inhaler Versus CFC Metered Dose Inhaler: Cumulative Dose-Response Study in Asthma Patients

References

• Pavia D. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997; 2(Suppl. 1)S5–S10
   Google Scholar
• Pavia D, McLeod L. The environmental impact of inhaled aerosols. Eur Respir Rev 1994; 4: 75–77
   Google Scholar
• Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5: 506–508
   PubMed Web of Science ®Google Scholar
• Brindley A, Sumby BS, Smith IJ, Prime D, Haywood PA, Grant A.C. Design, manufacture and dose consistency of the Serevent Diskus Inhaler. Pharm Tech Eur 1995; 7: 14–22
   Google Scholar
• Partridge M, Woodcock A. Metered dose inhalers free of chlorofluorocarbons. Br Med J 1995; 310: 684–685
   PubMed Web of Science ®Google Scholar
• Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim Nebulizer BINEB®: a new approach to inhalation therapy. Respiratory drug delivery V: program and proceedings, RN. Dalby, PR. Byron, SJ. Farr. Interpharm Press, Buffalo Grove, IL 1996; 187–193
   Google Scholar
• Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12(Suppl. 1)S19–S24
   PubMedGoogle Scholar
• Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma. Postgrad Med J 1996; 72: 151–156
   PubMedGoogle Scholar
• Matthys H. Inhalation delivery of asthma drugs. Lung 1990; 168(Suppl.)645–652
   Google Scholar
• Steed KP, Towse LJ, Freund B, Newman SP. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat® nebulizer. Eur J Pharm Sci 1997; 5: 55–61
   Web of Science ®Google Scholar
• Newman SP, Brown J, Steed K, Reader SJ, Kladders H. Lung deposition of fenoterol from Respimat®, a novel inhaler device for pulmonary drug delivery. J Aerosol Med 1997; 10: 268
   Google Scholar
• Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957–963
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225–244
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Report of Working Party Standardisation of Pulmonary Lung Function Tests. European Community for Steel and Coal. Eur Respir J 1993; 16: 5–40
   Web of Science ®Google Scholar
• Moss AJ. Prolonged QT-interval syndromes. J Am Med Assoc 1986; 256: 2985–2987
   Google Scholar
• Committee on Proprietary Medicinal Products. Note For Guidance on Statistical Principles for Clinical Trials. London, 18 March, 1998, CPMP/ICH/363/96
   Google Scholar
• Van Noord JA, Smeets JJ, Creemers JPHM, Greefhorst LPM, Dewberry H, Cornelissen PJG. Delivery of fenoterol via Respimat® a novel ‘soft mist’ inhaler. Respiration 2000; 67: 672–678
   Google Scholar
• Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault J-J. Improved delivery of ipratropium bromide using Respimat® (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med 2000; 94: 490–495
   PubMed Web of Science ®Google Scholar
• Kunkel G, Magnussen H, Bergmann K-C, Juergens UR, de Mey C, Freund E, Hinzmann R, Beckers B. Respimat® 9a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000; 67: 306–314
   PubMed Web of Science ®Google Scholar
• Von Berg A, Jeena P.M, Soemantri P.A, Vertruyen A, Razzouk H, Schmidt P, Gerken F. Comparison of efficacy and safety of fenoterol/ipratropium (F/I) inhaled from a new propellant-free soft-mist inhaler or from a metered-dose inhaler (MDI) with spacer in paediatric patients with asthma. [abstract] Eur Respir J 2000; 16(Suppl. 31)384S
   Google Scholar
• National Institutes of Health. Global Initiative for Asthma, Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Publication 95–3659. National Institutes of Health, National Heart Lung and Blood Institute, 1995
   Google Scholar
• Anonymous. Fenoterol in perspective. ADIS Press, Auckland 1989, ISBN: 0-86471-026-7
   Google Scholar
• Musch W, Vincken W, Noppen M, Gorus F. Metabolic effects of inhaled fenoterol in normal subjects. Chest 1992; 102: 1099–1103
   PubMed Web of Science ®Google Scholar
• Dolovich M, Ruffin RE, Roberts R, Newhouse M.T. Optimal delivery of aerosols from metered dose inhalers. Chest 1981; 80(6 Suppl.)911–915
   PubMed Web of Science ®Google Scholar
• Shenfield GM, Evans ME, Paterson JW. Absorption of drugs by the lung. Br J Clin Pharmacol 1976; 3: 583–589
   PubMed Web of Science ®Google Scholar